Although SGLT2, typically expressed in the renal proximal tubule, has also been reported to play a critical role in the development of pancreatic or breast cancer [60, 61], our data showed that SGLT1, but not SGLT2, is upregulated in response to EGFR TKI treatment, which supports glucose uptake and cellular viability in NSCLC cells with acquired TKI resistance. This evidence concerns the gene SLC5A2 and breast cancer.